P&T
Our
Other
Journal
MediMedia Managed Markets

 

Randy Vogenberg 2013

Beware of the Drug Shortage Domino Effect

Drug shortages might cause more drug substitutions which, in turn, could increase the chances of adverse events and the legal ramifications that go with them, says F. Randy Vogenberg, RPh, PhD. Newly created accountable care organizations need to be wary.

Who Will Pay for High-Cost Biologics?

Insurance coverage was never meant to handle new pharmaceutical breakthroughs on the radar — breakthroughs that can cost anywhere from $90,000 to $300,000 a year per patient, says F. Randy Vogenberg, RPh, PhD, principal of the Institute for Integrated Healthcare and a member of P&T’s Editorial Board. There will be pressure on everybody to find a way to somehow control these costs.

More Will Be Expected of Pharmacists

F. Randy Vogenberg, RPh, PhD, a member of P&T’s Editorial Board, says that in the fixed reimbursement system under health reform, pharmacists will need to balance clinical and economic considerations. The less expensive drug might not always be the answer.

What Changes are Coming for P&T Committees as a Result of the Affordable Care Act?

P&T committees will have to consider the economic fallout from their decisions as health reform advances, says F. Randy Vogenberg, RPh, PhD. That will be an adjustment.